Lenvatinib- and vadimezan-loaded synthetic high-density lipoprotein for combinational immunochemotherapy of metastatic triple-negative breast cancer

• Egile Nagusiak: Chao Zheng (Egilea), Wen Zhang (Egilea), Jinming Wang (Egilea), Yihui Zhai (Egilea), Fengqin Xiong (Egilea), Ying Cai (Egilea), Xiang Gong (Egilea), Binyu Zhu (Egilea), Helen He Zhu (Egilea), Hao Wang (Egilea), Yaping Li (Egilea), Pengcheng Zhang (Egilea)
• Formatua: Liburua
• Argitaratua: Elsevier, 2022-09-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Metastatic triple-negative breast cancer (TNBC) is the most aggressive type of breast cancer. Combination of systemic chemotherapy and immune checkpoint blockade is effective but of limited benefit due to insufficient intratumoral infiltration of cytotoxic T lymphocytes (CTLs) and the accumulation o...